About Cambrium
Cambrium is a materials science company that combines molecular biology, machine learning, protein engineering, and material science to design and produce high-performance materials. The company's platform uses molecular intelligence to predict how molecules will behave before they exist, then leverages living systems to build them at scale. Cambrium designs three core molecular systems—enzymes, polymers, and peptides—that can be applied across multiple industries. The company partners with organizations in apparel and footwear, personal care, mobility, home care, and building sectors to solve their most challenging performance problems. By working at the intersection of AI and bioscience, Cambrium creates materials that traditional chemistry cannot access, delivering products that outperform existing solutions. The company's approach is rooted in rigorous scientific methodology, combining curiosity with discipline to develop materials that embed themselves deeply into industries and carry them forward. Cambrium's team spans multiple scientific disciplines, united by the belief that better molecules can build a better world.
Mission & Story
Mission
Better molecules can build a better world.
Founding Story
Cambrium was founded on the belief that material science has stood still for decades, with molecules growing predictable and uninspired. The company exists to write the next chapter in humanity's material innovation story, bringing together scientists, engineers, and builders to advance beyond traditional chemistry.
Who It Serves
Milestones & Awards
Recent Milestones
Developed multiple material products including RevaBond, Microcellular Foam, Protective Coating, and Midsole Foam
Company Details
- Employees
- 1-10
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.